CTLA4 and melanoma: The reported 5-year survival rate was 18.2%, the median 5-year recurrence-free survival (RFS) was 27.6 months, and the median 5-year OS was 15.7 months when receiving 10 mg/kg ipilimumab in melanoma patients.304–306 However, when compared to CTLA-4 inhibitors, PD-1 inhibitors are more effective and have fewer side effects in melanoma patients.